Prostate Adenocarcinoma, Prostate Cancer, Prostate Cancer Metastatic
Conditions
Brief summary
Prostate cancer is a leading cause of mortality and morbidity. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC, T-cells and circulated tumor DNA in prostate cancer patients.
Interventions
None listed
Sponsors
Kazakh Research Institute of Oncology & Radiology
HKGepitherapeutics
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 90 Years
Inclusion criteria
* Informed consent: The patient must sign the appropriate approved informed consent documents in the presence of the designated staff
Exclusion criteria
* Pregnant women * Minors (subjects less than 18 years of age) * Prisoners * Patients having other than one cancer * Subjects unable to consent for themselves * Symptomatic of acute prostatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of prostate cancer | 6 months to 1 year | We will develop the linear model and a threshold value differentiating breast cancer from control based on the 100 patient training set. The model will be provided to the researchers: Methylation score=CG1\*b1+CG2\*b2+ CG3\*b3 + e CG1 is the methylation value of the first CG b1 is the regression coefficient for the first CG and e equals the intercept. We will develop the regression coefficient and intercept as well as the DNA methylation values for each patient for each CG. We will first compute the polygenic methylation score for each patient. Then based on the computer threshold based on the training cohort will call the samples as prostate cancer or not. |
Countries
Kazakhstan
Outcome results
None listed